[go: up one dir, main page]

PE20080742A1 - Perfil genico y procedimiento de identificacion - Google Patents

Perfil genico y procedimiento de identificacion

Info

Publication number
PE20080742A1
PE20080742A1 PE2007000676A PE2007000676A PE20080742A1 PE 20080742 A1 PE20080742 A1 PE 20080742A1 PE 2007000676 A PE2007000676 A PE 2007000676A PE 2007000676 A PE2007000676 A PE 2007000676A PE 20080742 A1 PE20080742 A1 PE 20080742A1
Authority
PE
Peru
Prior art keywords
immunotherapy
gene profile
cancer
identification procedure
gene
Prior art date
Application number
PE2007000676A
Other languages
English (en)
Inventor
Vincent Brichard
James Scott Clark
Thierry Coche
Swann Romain Jean-Thomas Gaulis
Olivier Gruselle
Frederic Lehmann
Jamila Louahed
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0610949A external-priority patent/GB0610949D0/en
Priority claimed from GB0700761A external-priority patent/GB0700761D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20080742A1 publication Critical patent/PE20080742A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

REFERIDA A UN PERFIL GENICO INDICATIVO DE UN PROBABILIDAD AUMENTADA DE UNA RESPUESTA A UNA INMUNOTERAPIA QUE COMPRENDE LA REGULACION DIFERENCIAL DE AL MENOS UN GEN DE ACTIVACION INMUNE, DONDE LA INMUNOTERAPIA ES UNA INMUNOTERAPIA DE CANCER ESPECIFICA DEL ANTIGENO MAGE QUE SON ANTIGENOS CODIFICADOS POR LA FAMILIA DE GENES DE ANTIGENO ASOCIADOS A MELANOMA. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE IDENTIFICACION DE DICHO PERFIL GENICO Y A UN KIT. EL PERFIL GENICO DE UN PACIENTE, EL PROCEDIMIENTO DE IDENTIFICACION DEL PERFIL GENICO Y EL KIT SON UTILES EN LA IDENTIFICACION DE PACIENTES CON CANCER QUE ES PROBABLE QUE RESPONDAN A LA INMUNOTERAPIA APROPIADA
PE2007000676A 2006-06-02 2007-05-31 Perfil genico y procedimiento de identificacion PE20080742A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0610949A GB0610949D0 (en) 2006-06-02 2006-06-02 Method
GB0700761A GB0700761D0 (en) 2007-01-15 2007-01-15 Method

Publications (1)

Publication Number Publication Date
PE20080742A1 true PE20080742A1 (es) 2008-08-06

Family

ID=38801855

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000676A PE20080742A1 (es) 2006-06-02 2007-05-31 Perfil genico y procedimiento de identificacion

Country Status (15)

Country Link
US (1) US20100021424A1 (es)
EP (23) EP2390358A1 (es)
JP (1) JP2009538607A (es)
KR (1) KR20090017655A (es)
AR (1) AR061136A1 (es)
AU (1) AU2007256383B2 (es)
BR (1) BRPI0712497A2 (es)
CA (1) CA2653949A1 (es)
CL (1) CL2007001571A1 (es)
EA (1) EA200802242A1 (es)
ES (1) ES2539042T3 (es)
MX (1) MX2008015372A (es)
PE (1) PE20080742A1 (es)
TW (1) TW200817680A (es)
WO (1) WO2007140958A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2227558A1 (en) * 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy
GB0816867D0 (en) * 2008-09-15 2008-10-22 Glaxosmithkline Biolog Sa Method
GB2466025A (en) * 2008-12-08 2010-06-09 Univ Francois Rabelais De Tour C3/ITGAM polymorphisms and cancer prognosis
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
US20120258076A1 (en) * 2009-12-16 2012-10-11 Hitachi Chemical Research Center, Inc. Method for characterizing host immune funtion by ex vivo induction of offensive and defensive immune markers
EP2380991A1 (en) 2010-04-20 2011-10-26 Universitätsklinikum Hamburg-Eppendorf Method of determining the metastatic potential of a tumor
CN103299188B (zh) * 2010-09-15 2017-03-15 阿尔玛克诊断有限公司 用于癌症的分子诊断试验
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
US9926604B2 (en) 2011-10-14 2018-03-27 The Regents Of The University Of California Multiplex PCR-based testing of cutaneous squamous cell carcinoma and pseudoepitheliomatous hyperplasia and methods for distinguishing the same
WO2014009535A2 (en) * 2012-07-12 2014-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
EP3164069B1 (en) * 2014-07-03 2020-09-16 University Of Virginia Patent Foundation Systems and methods for identifying and profiling muscle patterns
US20170298443A1 (en) * 2014-09-25 2017-10-19 Moffitt Genetics Corporation Prognostic tumor biomarkers
EP3234193B1 (en) * 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
JP6489900B2 (ja) * 2015-03-30 2019-03-27 株式会社ジャパンディスプレイ 入力装置及び表示装置
AU2016264623B2 (en) 2015-05-20 2022-06-30 Dana-Farber Cancer Institute, Inc. Shared neoantigens
EP3322406A4 (en) * 2015-07-14 2019-06-12 Atossa Genetics Inc. TRANSPARENT METHODS AND COMPOSITIONS FOR THE TREATMENT OF MAMMARY DISEASES
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US12303561B2 (en) 2017-04-03 2025-05-20 Biontech Us Inc. Protein antigens and uses thereof
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
JP7534962B2 (ja) 2018-06-19 2024-08-15 ビオンテック ユーエス インコーポレイテッド ネオ抗原およびその使用
GB201908565D0 (en) * 2019-06-14 2019-07-31 Cray Innovation Ab Method of stratifying subjects into sub-groups for therapeutic treatment
CN114540504B (zh) * 2022-04-27 2022-07-08 广州万德基因医学科技有限公司 用于预测肺鳞癌患者免疫疗效的标志物组及系统

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1001034B (el) * 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
EP1584685B1 (en) 1998-02-05 2011-04-13 GlaxoSmithKline Biologicals SA Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination
WO2000009159A1 (en) 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
EP1147190B1 (en) 1999-01-29 2010-07-14 Corixa Corporation Her-2/neu fusion proteins
WO2000053748A2 (en) 1999-03-11 2000-09-14 Smithkline Beecham Biologicals S.A. Casb618 polynucleotides and polypeptides and their use
CZ303515B6 (cs) 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvantní prostredek
HUP0300054A3 (en) 2000-02-23 2012-09-28 Smithkline Beecham Biolog Tumour-specific animal proteins
AUPR077900A0 (en) * 2000-10-13 2000-11-09 Tvw Telethon Institute For Child Health Research Immunodiagnosis
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
JP2004529888A (ja) * 2001-02-26 2004-09-30 ゲゼルシャフト フュア ビオテヒノロジッシェ フォルシュング エムベーハー （ゲーベーエフ） インターフェロン調節因子−１／ヒトエストロゲン受容体融合タンパク質および癌を治療するためのその使用
WO2002076469A1 (en) * 2001-03-27 2002-10-03 Baylor College Of Medicine A novel technology of intracellular delivery of dna oligonucleotides to improve drug activity
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
EP2131198B1 (en) * 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
WO2003050257A2 (en) * 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
CZ2004862A3 (cs) 2002-02-04 2005-01-12 Corixa Corporation Nové imunoefektorové sloučeniny
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
AU2003246411A1 (en) 2002-06-11 2003-12-22 Glaxo Group Limited Immunogenic compositions
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004076565A2 (en) * 2003-02-25 2004-09-10 Technical Knockout, Inc. Improved coated weight plates, dumbbells and method of manufacture
CA2516182A1 (en) * 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Expression profiles for breast cancer and methods of use
JP2007516692A (ja) * 2003-03-07 2007-06-28 アビアラデックス，インコーポレイティド 乳癌の徴候
EP1608964A4 (en) 2003-03-14 2009-07-15 Peter Maccallum Cancer Inst CREATING AN EXPRESSION PROFILE OF TUMORS
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
WO2004105573A2 (en) * 2003-05-21 2004-12-09 The Wistar Institute Of Anatomy And Biology Method of diagnosis of cancer based on gene expression profiles in cells
WO2004111603A2 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2527680A1 (en) 2003-05-30 2005-06-02 Astrazeneca Uk Limited Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
CN1842603B (zh) * 2003-06-27 2013-09-11 株式会社国际癌症免疫研究所 选择适于wt1疫苗患者的方法
ES2311852T3 (es) * 2003-08-28 2009-02-16 Ipsogen Identificacion de un modelo especifico de la expresion del gen erbb2 en cancer de mama.
JP2007507243A (ja) 2003-10-03 2007-03-29 バイエル・フアーマシユーチカルズ・コーポレーシヨン 遺伝子発現プロファイルおよび使用方法
US20070110710A1 (en) * 2003-11-05 2007-05-17 New England Medical Center Hospitals, Inc. Treatment with immunoregulatory t cells
WO2005054496A1 (ja) * 2003-12-02 2005-06-16 Orient Cancer Therapy Co., Ltd. 細胞動態の検査方法
WO2005059543A1 (en) * 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor h963 (h963)
US8187805B2 (en) * 2004-02-09 2012-05-29 Fuso Pharmaceutical Industries, Ltd. Method of detecting nucleic acid and utilization thereof
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
CA2571070A1 (en) * 2004-06-17 2006-01-05 Mannkind Corporation Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
WO2006012641A2 (en) * 2004-07-30 2006-02-02 Oregon Health And Science University Methods for detecting and treating autoimmune disorders
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US20060110371A1 (en) * 2004-11-23 2006-05-25 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
EP1831684A4 (en) 2004-11-30 2009-03-11 Veridex Llc LUNGENKREBSPROGNOSTIK
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
WO2006073982A2 (en) * 2004-12-30 2006-07-13 Regents Of The University Of California Bispecific molecule comprising ligands for cell-surface protein and t-cell surface protein
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
GB0504302D0 (en) 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
KR20080004551A (ko) 2005-04-01 2008-01-09 엔씨씨 테크놀로지 벤쳐스 피티이 리미티드 유방암 분류에 관한 재료 및 방법
JP2008535494A (ja) * 2005-04-07 2008-09-04 サグレシュ ディスカバリー， インコーポレイテッド 癌関連遺伝子（ｐｒｌｒ）
EP1869224A4 (en) * 2005-04-15 2009-11-18 Oncomethylome Sciences Inc METHYLATION MARKERS FOR THE DIAGNOSIS AND TREATMENT OF CANCERS
EP1910564A1 (en) 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
WO2007008583A2 (en) * 2005-07-07 2007-01-18 Kohne David E Improved protein expression comparison assay results and applications
KR20080068848A (ko) * 2005-10-11 2008-07-24 메르크 파텐트 게엠베하 케모카인 발현의 ｅｇｆｒ 의존적 조절 및 그의 종양 및부작용의 치료 및 진단효과
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Also Published As

Publication number Publication date
WO2007140958A3 (en) 2008-07-03
EP2390358A1 (en) 2011-11-30
EP2390361A1 (en) 2011-11-30
BRPI0712497A2 (pt) 2012-09-18
CL2007001571A1 (es) 2008-05-16
EP2258874B1 (en) 2015-03-18
EP2390356A1 (en) 2011-11-30
ES2539042T3 (es) 2015-06-25
EP2390368A1 (en) 2011-11-30
EP2390359A1 (en) 2011-11-30
EP2392672A1 (en) 2011-12-07
EP2392671A1 (en) 2011-12-07
CA2653949A1 (en) 2007-12-13
EP2258874A1 (en) 2010-12-08
EA200802242A1 (ru) 2009-08-28
MX2008015372A (es) 2009-03-23
JP2009538607A (ja) 2009-11-12
EP2032719A2 (en) 2009-03-11
WO2007140958A2 (en) 2007-12-13
EP2390357A1 (en) 2011-11-30
EP2390363A1 (en) 2011-11-30
EP2390367A1 (en) 2011-11-30
EP2390365A1 (en) 2011-11-30
US20100021424A1 (en) 2010-01-28
EP2390369A1 (en) 2011-11-30
EP2390366A1 (en) 2011-11-30
EP2392675A1 (en) 2011-12-07
AR061136A1 (es) 2008-08-06
KR20090017655A (ko) 2009-02-18
EP2390353A1 (en) 2011-11-30
EP2390360A1 (en) 2011-11-30
EP2390362A1 (en) 2011-11-30
EP2390355A1 (en) 2011-11-30
EP2390354A1 (en) 2011-11-30
AU2007256383B2 (en) 2013-06-06
TW200817680A (en) 2008-04-16
AU2007256383A1 (en) 2007-12-13
EP2392673A1 (en) 2011-12-07
EP2390364A1 (en) 2011-11-30
WO2007140958A9 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
PE20080742A1 (es) Perfil genico y procedimiento de identificacion
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
MX2018010361A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
ATE466084T1 (de) Hla-a24-restringiertes krebsantigenpeptid
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
CY1114661T1 (el) Ταυτοποιηση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια
RS20170595A1 (sr) Tretman sa anti-vegf antitelima
PL2733493T3 (pl) Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu
EP3064584A3 (en) Micro rna-based methods and compositions for the diagnosis, prognosis and treatmentof gastric cancer
MX2007004176A (es) B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
AR102538A1 (es) Métodos de selección de la línea celular t y donante de la misma para la terapia adoptiva celular
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP3299387A3 (en) Identification of tumor-associated markers for diagnosis and therapy
EA201070863A1 (ru) Способы детекции признаков заболеваний или состояний в жидкостях организма
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
AU2004205878A8 (en) Gene expression markers for breast cancer prognosis
AR054536A1 (es) Terapia de combinacion de anticuerpo anti- ctla -4 y oligodesoxinucleotido sintetico que contiene motivo cgp para el tratamiento del cancer
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
UA106756C2 (uk) Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа
EP2420509A3 (en) Novel marker genes for regulatory T cells from human blood
CO6382138A2 (es) N-cadherina: blanco para diagnosis y terapia de cáncer
BR112014023496A2 (pt) mutantes c-raf que conferem resistência a inibidores de raf
PL1954830T3 (pl) Sposoby i zestawy do prognozowania przebiegu raka sutka
EP2277918A3 (en) Mhc class I and II peptide antigens derived from tumour antigen 5t4
AU2018256601A1 (en) Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal